Purpose of Review The goal of the present paper is to review current literature supporting the occurrence of fundamental changes in brain energy metabolism during the transition from wakefulness to sleep. Recent Findings Latest research in the field indicates that glucose utilization and the concentrations of several brain metabolites consistently change across the sleep-wake cycle. Lactate, a product of glycolysis that is involved in synaptic plasticity, has emerged as a good biomarker of brain state. Sleep-induced changes in cerebral metabolite levels result from a shift in oxidative metabolism, which alters the reliance of brain metabolism upon carbohydrates. Summary We found wide support for the notion that brain energetics is state dependent. In particular, fatty acids and ketone bodies partly replace glucose as cerebral energy source during sleep. This mechanism plausibly accounts for increases in biosynthetic pathways and functional alterations in neuronal activity associated with sleep. A better account of brain energy metabolism during sleep might help elucidate the long mysterious restorative effects of sleep for the whole organism. 
Introduction
Sleep is a necessary aspect of life for most animals. Greater vulnerability to predation and other environmental challenges during loss of consciousness implies that sleep must play some essential function in the health of the organism. However, sleep is much more than a state of detachment from the environment, if only because of the high-energy demand of internally generated and internally directed neural activity. The relationship between wakefulness, conscious awareness, behavioral responsiveness, and brain energy utilization is complex [1] [2] [3] . Quantitatively, the increments in cerebral metabolic requirements to sustain consciousness are surprisingly small [4] , while current research supports the notion that sleep is almost as metabolically expensive as wakefulness for the brain [5] .
There is a growing realization that brain functional state and energetics are not separable entities [6] . From an evolutionary viewpoint, it is remarkable that molecules involved in central cellular metabolism like glutamate and ATP, as well as glucose, lactate, and other metabolites have been co-opted to have signaling functions in brain [7] . As an illustration, elevated extracellular glucose levels inhibit wake-promoting orexinergic neurons in the lateral hypothalamus [8] and excite sleep-promoting GABAergic neurons in ventrolateral preoptic nucleus [9] . Other studies link elevated extracellular lactate levels with the activation of wake-and attention-promoting noradrenergic neurons in the locus coeruleus [10] . Monocarboxylates, ketone bodies and fatty acids can also activate intracellular signaling cascades in different brain cell types through a variety of cell-surface G-protein-coupled receptors (e.g., hydroxycarboxylic acid receptors) [11] [12] [13] . Furthermore, energy substrates can even have direct or indirect effect on neuronal ion channels. For example, the medium-chain fatty acid decanoate and the monocarboxylate lactate can modulate the activity of AMPA and NMDA receptors, respectively [14, 15] . Regulation of gene expression is also among the non-energetic targets of some substrates. For example, the short-chain fatty acid butyrate and the ketone body β-hydroxybutyrate (β-HB) inhibit brain histone deacetylases, which can have widespread effects on gene expression [16, 17] . Our knowledge of this kind of refined cerebral metabolic-sensing pathways is still in its infancy, but we shall argue that such mechanisms govern the transitions between and maintenance of state-specific neuronal activity changes and synaptic plasticity. In the following, we refrain from further examination of the novel signaling roles of energy metabolism substrates, but instead focus in describing the homeostatic changes in cerebral metabolic substrates and pathways occurring in the transition to the sleep state.
Global Changes in Brain Energy Metabolism During Sleep

Respiratory Quotient
During sleep, the whole-body respiratory quotient (RQ) decreases by about 5% in humans (from~0.9 to~0.86) relative to wakefulness (Table 1 ; Fig. 1 ), reflecting reduced oxidation of carbohydrates. Likewise, the respiratory exchange ratio, which similarly indicates carbohydrate dependence, decreases by~10% during the resting/sleep state in rodents with ad libitum access to a standard chow diet [70, 71] . The relative dependence on fatty acid oxidation during sleep and carbohydrate oxidation during wakefulness varies with food source, as well as daily eating and behavioral activity patterns [70] . However, the state change in itself also plays a role independent of these parameters and of circadian time. Thus, upon the transition to wakefullness, there is a shift in RQ toward higher utilization of carbohydrates compared with sleep, which is matched by a drop in the rate of fatty acid oxidation in the brain [72, 73] . Indeed, fatty acid oxidation peaks midway through the sleeping period (when the nadir in carbohydrate oxidation occurs) and decreases to nearly zero at the end of an 8-h sleeping period [18] . This temporal pattern tracks the concentrations of non-esterified or free fatty acid (FFA) levels in the circulation (Table 1 ). Blood FFA levels rise toward the end of a period of wakefulness, attaining a zenith at the beginning of the sleep period and decline again toward a nadir at the beginning of the next wake period (references in Table 1 ; Fig. 1c) . While the diurnal fluctuation in fatty acid and glucose metabolism are under circadian genetic regulation [71] , metabolism is also influenced by environmental factors such as diet and sleep [74] . Increased blood FFA levels during early morning sleep deprivation have been found to correlate with elevated norepinephrine (NE) levels during this condition [75] , probably reflecting increasing sympathetic tonus during fasting, which promotes lipolysis in adipose tissue [23, 75] . FFAs released from adipose tissue to the circulation during sleep are utilizated in different organs for ATP generation, which manifests in the decreased RQ during this period.
The RQ of the brain in unanesthetized mammals is approximately unity (range 0.95-1.10) [76, 77] , consistent with glucose being the predominant cerebral energy fuel under normal waking conditions [78] . Although the precise relation between brain state and RQ is unknown, early evidence obtained in cats indicated brain RQ < 0.9 and oxidation of substances other than carbohydrates under alpha-chloralose anesthesia [79] (but see also [80] ). Interestingly, brain RQ in human preterm newborns has been anecdotally reported to be 10% lower than in adults [81] , which would be consistent with higher utilization of fats by the neonatal brain [82] .
Oxidative Shift
During quiet waking, the cerebral oxygen-glucose utilization stoichiometry (OGI, oxygen-glucose index) falls slightly below the theoretical value of 6 for complete glucose oxidation to around 5.5, and during active waking the OGI decreases further to 4.5-5, indicating that a substantial fraction (8 to 25%) of the glucose taken up by the brain is not locally oxidized [83] . The excess carbons from glycolysis are retained as lactate, which is formed at a high rate in the brain under physiological waking conditions (see below) [84] . During sleep, functional changes in brain activity are accompanied by alterations of major metabolic pathways and corresponding metabolite levels (Table 2 ; Fig. 1b) . Specifically, sleep is associated with a substantial drop in the cerebral metabolic rate of glucose (CMRglc) (− 40% on average), which is not matched by a corresponding decrease in the oxygen utilization (CMRO 2 ) (− 15% on average). This imbalance is reminiscent of what happens during sensory stimulation, Fig. 1 Main metabolic changes occurring in the body and brain during sleep. Adults spend 70-80% of the total sleep time in non-REM (NREM). NREM sleep is characterized by low muscle tonus, no food and water intake, and lower body temperature as compared with wakefulness, while oxygen availability remains high, all of which conditions may favor β-oxidation of fats over carbohydrates. Concordantly, the respiratory quotient, an indicator of whole body fuel utilization, is~5% lower during NREM sleep, representing a higher level of lipid oxidation, compatible with the fasting state. a In the NREM sleep state, the reduction in brain glucose metabolism stoichiometrically exceeds the reduction in brain oxygen consumption, although both glucose and oxygen availability remain high. Lactate levels are lower, reflecting decreased production from glycolysis, as well as increased washout. Neuronal firing activity is lower, as is the tissue/extracellular level of glutamate. The antioxidant capacity, represented by glutathione level and glutathione peroxidase (GSH-per) activity, is increased during sleep. b Biosynthetic pathways such as the pentose phosphate pathway, glycogenesis, de novo lipogenesis, cholesterogenesis and protein synthesis are active during sleep, restoring the metabolic pools that are utilized during wakefulness to support neuronal activity and signaling i.e. glycogenolysis, lipolysis and membrane remodeling. We propose that fatty acid oxidation is increased during sleep, replenishing tricarboxylic acid (TCA) cycle intermediates and providing metabolites and ketone bodies for neurons. The fatty acid oxidation pathway could be fueled by FFAs dervied from circulation during the sleep state and/or by "toxic" lipid species released during lipolysis. NE is a known contributor to wake-related processes such as awareness, attention, and focus and is known to stimulate metabolic processes in the brain, i.e., aerobic glycolysis and glycogenolysis in astrocytes. In peripheral tissues, activation of adrenergic receptors stimulates lipolysis and NE blocks oxidation of long-chain fatty acids. It is presently unknown whether NE has a similar role in the brain. c Blood levels of insulin, glucose, and lactate are increased by wakefulness-associated activities, such as muscle movement and food intake, and are lower during the inactive sleep state. Conversely, a rise in circulating fatty acid levels followed by an increase in ketone bodies are observed during the sleep state, when food intake is absent. Graphical illustrations and pathways are estimated based on studies listed in Tables 1, 2, and 3 when the CMRglc rises out of proportion compared with oxygen consumption (Table 2) , which is known as "metabolic uncoupling." Brain glucose and lactate concentrations reflect these changes in glycolysis and respiration, consistently indicating a more oxidative condition in the sleep state than during wakefulness. In particular, estimated values of OGI exceeding 6, together with decrease in brain lactate production and increase in lactate efflux from the brain during sleep (see below), indicate substantial oxidation of non-carbohydrate sources, as suggested elsewhere [5] .
Summary
During sleep, the CMRglc decreases much more than does CMRO 2 . Moreover, the transition into sleep is accompanied by a reduction in whole-body RQ. These findings suggest that the brain, like the rest of the body, shifts toward oxidation of fatty acids and ketone bodies released into the circulation during this period.
Substrates and Pathways of Brain Energy Metabolism During Sleep
Carbohydrates The brain consumes a large fraction of the body's energy budget (approximately 20% in humans) and is dependent on a continuous supply of glucose and oxygen from the blood. Although glucose is the preferred energy substrate of the adult brain, there is considerable capacity to switch to utilization of other compounds under specific conditions (e.g., ketone bodies under starvation or hyperketonemia, lactate under intense exercise or hyperlactatemia, and acetate under ethanol administration or hyperacetatemia). The awake brain maintains a relatively high glycolytic metabolism relative to respiration, resulting in net lactate production irrespective of adequate oxygenation. This phenomenon, which is termed aerobic glycolysis, is exacerbated during active waking (e.g., sensory or cognitive stimulation) ( Table 2 ). Aerobic glycolysis is enhanced by NE signaling [84] and is thought to be a correlate of goal-directed behavior, learning, and memory [7] . Furthermore, NE is a driver of several waking-related processes in brain and is also known to control metabolic processes in the periphery and in the brain, such as glycogen mobilization in liver hepatocytes or brain astrocytes [85] . The cellular mechanisms underlying the high cerebral rates of aerobic glycolysis (whether derived from glucose or glycogen pools) during wakefulness are not understood. Experimental evidence indicates that up-regulation of glycolytic metabolism might serve specific subcellular processes, e.g., presynaptic neurotransmitter vesicle turnover and/or dendritic spine repolarization, but the details of this relationship are largely unknown (reviewed by [5] ).
Sleep is associated with increase in brain glucose levels that is not paralleled by concomitant increases in blood glucose levels (see Tables 1; 2) , which indicates reduced cerebral glucose metabolism. The brain tissue lactate concentration falls rapidly following state transition from wakefulness into sleep. Lactate is the only metabolic compund thus far identified as a good biomarker of sleep [37] . The reduction in brain lactate levels is consistent with reduced cerebral glycolysis, but also reflects enhanced lactate drainage through the brain glymphatic system during sleep [86] . Furthermore, sleep brings about decreased degradation of glycogen (the sole glucose storage pool in the brain) to lactate, resulting in elevated tissue glycogen content [87] . As discussed above, the magnitude of CMRO 2 falls much less during sleep than does the aggregated utilization of glucose and glycogen. The larger dynamic range in the magnitude of CMRglc across the sleep-waking cycle or in response to stimulation may reflect functional alterations in the activity of neurons and corresponding participation of astrocytes in homeostasis of neuroactive compound and synaptic plasticity [5, 88] . The baseline glucose consumption during sleep is accounted for in part by the pentose phosphate pathway (PPP), which is implicated in the scavenging of reactive oxygen species (ROS). Interestingly, the flux through PPP is closely related to NADPH redox state and is under the control of circadian rhythms [89] . Glucose is also the carbon source in other biosynthetic pathways departing from the glycolytic pathway and tricarboxylic acid cycle. In addition to increased cerebral glycogen formation, the rates of biosynthesis of lipids (see below, Fig. 1b ) and proteins are enhanced during sleep. Particularly, brain protein synthesis increase occurs during slow wave sleep [67••, 90-92] , in a process thought to subserve memory consolidation [93] . Overall, the net decline in brain glucose consumption during sleep indicates decreasing neural activity in conjunction with elevated demands for the brain's antioxidant system and biosynthesis of proteins and lipids. This complex metabolic pattern might explain the multiphasic changes in brain glucose levels during sleep, which stand in contrast with the almost monophasic decrease in lactate levels [37] .
Long-Chain Fatty Acids
Several studies of the adult rodent, non-human primate and human brains have shown that both non-esterified mediumchain fatty acids [94] and long-chain saturated fatty acids enter the brain. Up to 50-60% are rapidly oxidized while the rest are incorporated into soluble metabolites, especially glutamine and glutamate, or into other lipid classes within less than 10 min after infusion [ All of these aspects of metabolic syndrome are known to be accompanied by increases in circulating FFA levels [100, 101] . In circulation, FFAs are almost completely bound to albumin. The albumin-FFA complex may cross the bloodbrain barrier (BBB) by passive diffusion [102] , perhaps augmented by caveolin-1-mediated transcytosis across endothelial membranes [103, 104] . Although the transcytotic activity of the BBB is of low capacity, this unique feature of the brain endothelium is modulated by Mfsd2a, the docosahexanoic acid (DHA) transporter expressed in brain endothelial cells [69] . Knocking out the expression of Mfds2a increases the BBB permeability to FFAs by increasing the rate of transcytosis across the endothelium [69] . Interestingly, mRNA expression of Mfds2a in the adult mouse brain is significantly decreased during the sleep period (Table 3; unpublished observations), suggesting that a higher rate of transcytosis could take place during sleep. In addition, the mRNA levels of the fatty acid transporter Fatp1 (Slc27a1) and the fatty acid-binding proteins Fabp7 [105] , Fabp5, and Fabp3 are all increased in the mouse cortex/hippocampus during the sleep period (unpublished observations), implying a higher capacity for fatty acid transport and binding during sleep compared with wakefulness. The fatty acid transporter protein Fatp1 and the binding proteins Fabp7 and Fabp5 are expressed predominantly in astrocytes [106•] . Because they line the cerebral vasculature with perivascular endfeet, astrocytes are well positioned for taking up blood-borne fatty acids. In addition, the rate of diffusion of fatty acids through the basal lamina to the interstial fluid is substantially lower than other energy substrates, e.g., glucose. Accordingly, fatty acid oxidation is known to take place predominantly in astrocytes throughout the brain, with the exception of regions with incomplete BBB, such as the hypothalamus, circumventricular organs, and neurogenic regions [107, 108] . The expression of the carnitine palmitoyltransferase enzymes CPT1a and CPT2 by astrocytes [109] enables these cells to oxidize long-chain fatty acids (length C14-C20) such as palmitic acid (16:0), oleic acid (18:1), and stearic acid (18:0), which are the most abundant FFAs in the blood [110] . Diurnal oscillations in expression and activity of CPT1a and other enzymes of the fatty acid oxidation pathway have been observed in several organs, such as the liver [71] , the gut [111] , and the retina [112] . Thus, the mitochondria in these organs seem to shift their reliance on glucose vs. fatty acids according to the time of day. We (unpublished observations) and others ( Table 3) have observed that several genes involved in both mitochondrial (including Cpt1a) and peroxisomal fatty acid oxidation have higher expression in brain during the sleep period, which might indicate that brain mitochondria accommodate higher fatty acid oxidation during this state.
Concentrations of several lipid species fluctuate diurnally in the circulation. The levels of medium-and long-chain acylcarnitines (intermediates generated during fatty acid oxidation) and of membrane lipids are among the most variable across the sleep/wake cycle and have been found to be affected by sleep deprivation [27] [28] [29] 113] (Table 3; unpublished observations), albeit with a modest range between peak and nadir. The finding that these perturbations in lipid metabolism are even more pronounced during sleep deprivation suggests that they are a "product" of wakefulness rather than being solely controlled by circadian processes. In the perfused rat liver, NE infusion attenuated fatty acid oxidation and ketogenesis from long-chain fatty acid, while promoting glycogenolysis and glycolysis [114] . Because there was no corresponding effect of NE on medium-chain fatty acid metabolism, the impeding effects of NE presumably occurs at the level of the CPT. One could speculate that, as in the liver, NE would affect astrocyte fatty acid metabolism during wakefulness. Indeed, irreversible blocking of CPT has been shown to increase lipid incorporation into phospholipids and triacylglycerols in brain, while decreasing the oxidized fraction [97, 115] . This rechanneling of lipid metabolism, from oxidation to incorporation in plasma membranes, could be a factor in the change in astrocytic morphology during state transition [68] . Upon waking, the resumption of brain NE signaling leads to expansion of the volume and surface area of astrocyte distal processes [116] , allowing them to engage more closely with neuronal synapses and the vasculature during wakefulness. Conversely, transition to sleep sees a decrease in surface area of peripheral astrocytic processes, and deprivation of sleep provokes phagocytosis of synaptic elements by astrocytes and microglia [117] . Although not previously investigated, it is also possible that astrocytes metabolize substantial amounts of plasma membrane phospholipids during sleep by β-oxidation (eventually followed by ketogenesis, and/ or lipid synthesis. [68] or oligodendrocytes (CNP+) [98] were isolated using the BAC-TRAP technique
Short-and Medium-Chain Fatty Acids
Although it has been known for several years that the brain and, in particular, its astrocyte population, expresses the enzymes of the fatty acid oxidation pathway, there remains a common belief that this normally contributes little to the brain's energy budget, which is largely met by glucose (see above). Some of the reasons for the persistence of this notion are (i) free fatty acids do not easily cross the BBB, (ii) the brain does not have any capacity to store lipids, thereby limiting the availability of substrate, and (iii) lipid oxidation generates a large amounts of neurotoxic ROS [118, 119] . Moreover, the wakefulness-sleep transition is accompanied by a surge in cerebral ATP levels and a concurrent reduction in phosphorylated AMP-activated protein kinase (p-AMPK) that have been related, at least in part, to the decrease in brain's energy demand [53, 120] . Activation of the nutrient sensor AMPK pathway is known to release intracellular stores of the nuclear receptor peroxisome proliferator activated receptor α, which is one of the key transcription factors facilitating fatty acid oxidation and ketogenesis. In addition, p-AMPK inactivates by phosphorylation acetyl-CoA carboxylase, the rate-limiting enzyme of fatty acid synthesis. This results in decreasing malonyl-CoA concentration, disinhibition of CPT enzymes, and more efficient transport of long-chain fatty acids into mitochondria. This cluster of events is seemingly incompatible with an increase in fatty acid oxidation during sleep, even though AMPK activation can also take place independently of an increasing AMP:ATP ratio, e.g., via ROS signaling [121] . Although these criticisms are presently not solved, evidence has been provided above supporting the model that long-chain fatty acid oxidation in the brain is favored during sleep. Moreover, oxidation of short-and mediumchain fatty acids (length C3-C12) does not suffer from the limitations concerning long-chain fatty acids. Thus, shortand medium-chain fatty acids might represent additional substrates for β-oxidation. Compared with long-chain fatty acids, short-and medium-chain fatty acids have several advantages as energy substrates, given that (i) they are not albumin-bound in blood and do not require fatty acid transport or binding proteins for blood-brain translocation, cellular uptake, and intracellular transport; (ii) they are independent of CPT activity for entry into mitochondria; and (iii) they have very low protonophoric activity for mitochondria and therefore do not appreciably impede the electron transport chain. Indeed, short-and mediumchain fatty acids readily cross both the BBB as well as the inner mitochondrial membrane via monocarboxylate transporters (MCT) and their oxidation does not result in excessive ROS generation (reviewed by [122] ). The capacity of some short-and medium-chain fatty acids to reduce the concentration of fructose 2,6-bisphosphate and hence to impede glycolysis at the 6-phosphofructo-1-kinase step [123, 124] can also explain the decrease in cerebral glucose uptake and utilization observed during sleep. Interestingly, fructose 2,6-bisphosphate is a modulator of glycolysis in astrocytes but not neurons [125] . The gene expression level of Pfkfb3, which encodes the fructose 2,6-bisphosphatase 3 enzyme, which catalyzes fructose 2,6-bisphosphate synthesis found specifically in astrocytes and microglia/macrophages, falls significantly in the adult mouse hippocampus/cortex during the sleep period (unpublished observations). The effect of fatty acids on astrocytic metabolism appears to be dependent on (even/odd) chain length and upon concentration. For example, decanoate can have a stimulatory effect on astocytic glycolysis [126] . Short-and medium-chain fatty acid utilization in brain might also be under the control of transport systems, since the efficiency for their translocation by MCTs declines with increasing chain length. Notably, octanoate accounts for~20% of total brain metabolism in ketamine-xylazine anesthetized rats [94] and furthermore stimulates ketogenesis in astrocytes [126] .
Ketone Bodies
In the liver, free fatty acids undergo β-oxidation followed by ketone body synthesis. Several studies have found increased levels of the main ketone bodies β-HB and acetetoacetate (AcAc) in the circulation during the sleeping period in humans and rodents (Table 1) . It should be mentioned that this phenomenon depends upon time-restricted feeding during the active period [26] , which probably explains why the increase during sleep is not evident in all studies (Table 1) . Astrocytes also have the capacity to produce ketone bodies from fatty acids [108] , and astroglial ketogenesis may well occur during sleep as a by-product of fatty acid oxidation, just as in the liver [22] . However, we are unaware of any studies showing that the proteins (or genes) involved with ketogenesis, i.e., HMG-CoA synthase (Hmgcs2) and/or HMG-CoA lyase (Hmgcl), which convert acetoacetyl-CoA to AcAc in the ketogenetic pathway, are increased in the sleep period compared with wakefulness. Nonetheless, during the sleep period, there is increased expression of Bdh1, the gene encoding β-hydroxybutyrate dehydrogenase 1, which is responsible for the interconversion between β-HB and AcAc in a mitochondrial NAD + /NADH-dependent reaction. We also find (unpublished observations) increased expression in Acss2, Acat2, and Aacs, encoding the enzymes responsible for converting acetate, cytosolic acetyl-CoA, and the ketone body AcAc, to acetoacetyl-CoA (the key substrate in cholesterogenesis), as well as increased expression of the gene Acaca encoding acetyl-CoA carboxylase 1, which is responsible for converting cytosolic acetyl-CoA to malonyl-CoA (the first step in de novo lipogenesis). The above-mentioned reactions could take place in oligodendrocytes and astrocytes (http://www.brainrnaseq.org/). We and others have also observed increased expression during sleep of the genes encoding the monocarboxylate transporters MCT1 and MCT2, which transport lactate, short-and medium-chain fatty acids, and ketone bodies across the plasma membrane (Table  3 ; unpublished observations). MCT1 and MCT2 are both expressed in endothelial cells, whereas MCT1 is also expressed in astrocytes and oligodendrocytes, and MCT2 is the primary transporter in neurons [106•, 127] . Altogether, this could suggest that the ketone bodies β-HB and AcAc produced by the liver during sleep are transported across the BBB, where some of the β-HB is converted to AcAc by BDH1 and proceeds further to acetoacetyl-CoA for cholesterogenesis or to malonyl-CoA for de novo lipogenesis, probably occuring in oligodendrocytes [30•] .
Ketone bodies can also be utilized as an energy source by neurons and astrocytes, and cerebral ketone bodies utilization increases systematically with the progression of brain state from wakefulness to anesthesia to isoelectricity [31, 128] . Before their utilization for energy production, the ketone bodies must first be converted to acetyl-CoA in the ketolytic reaction catalyzed by succinyl-CoA-3-oxaloacid CoA transferase, also known as the Oxct1 gene product 3-oxoacid CoA-transferase 1. We have not found evidence for altered expression of this gene or protein between sleep and wakefulness. However, as with all other results based on mRNA expression data, the negative findings do not exclude the possibility that the enzymatic activity increases during sleep. FFAs taken up by astrocytes can support ketone body synthesis independent of fatty acid oxidation [129] and may well be shuttled to neurons [130] . Utilization of ketone bodies for energy production during sleep provides a further explaination for the decrease in cerebral glycolysis [131, 132] .
The effect of ketone bodies on brain function have been extensively studied in relation to the ketogenic diet and protection from seizures [133] . Findings in these studies may also be relevant for the potential function of ketone bodies during sleep, when neuronal activity is dampened. In this regard, ketone bodies are known to mediate metabolic changes through anaplerosis, to decrease the glutamate/GABA ratio and brain glycolytic activity, inhibit histone deacetylases, which reduces ROS formation (see [133] for review). In one study investigating directly how ketone bodies influence sleep, central injection of AcAc increased slow wave activity, decreased rapid eye movement (REM) sleep, and reduced glutamate levels in the lateral ventricle, while injection of β-HB did not have any such effects [134•] . Along the same lines, AcAc administration can reduce glutamatergic neurotransmission by inhibiting vesicular uptake of glutamate [135] . Cortical extracellular glutamate levels are directly associated with state changes across the sleep-wake cycle. In the rat cortex, extracellular glutamate increases rapidly and progressively during onset of wakefulness or REM sleep and decreases during non-REM sleep [136•] (Fig. 1a) . Accordingly, genetic activation of glutamatergic neurons in Drosophila increased their periods of wakefulness during both day and nighttime [137] . Thus, AcAc may influence the firing of neurons as well as state changes by regulating the presynaptic release of glutamate in the brain.
It is abundantly clear that ketone bodies serve not only a metabolic role, but also function as signaling molecules [138] . To date, two G-coupled receptors are known for beta-HB, namely GPR109A, which is encoded by the Hcar2 gene and free fatty acid receptor 3 (FFAR3) also known as GPR41. In the brain, GPR109A is located on microglial cells, and activation of this receptor by beta-HB has anti-inflammatory effects [139] FFAR3 is not expressed in the central nervous system, but rather in the peripheral nerves [140] , where its activation suppresses sympathetic activity [141] . Alltogether, beta-HB signaling via peripheral FFAR3 receptors is unlikely to exert direct and acute effects on the sleep/wake state, but a shift toward parasymphathetic dominance occurs during non-REM sleep, whereas the sympathetic/parasympathetic balance during REM sleep resembles that of wakefulness [142] .
Summary
Catabolism of glucose and glycogen via aerobic glycolysis is a hallmark of wakefulness, whereas transition to sleep is marked by decreased brain lactate levels, due to decreased production as well as increased glymphatic clearance. Most likely, the rise in oxygen-glucose index during sleep is not due to reduced aerobic glycolysis, i.e., more lactate oxidation, but rather to a shift towards utilization of fatty acids and ketone bodies as energy substrates. FFA passing from circulation to the brain supports ATP production via mitochondrial β-oxidation (~60%). Astrocytes are the primary cell type carrying out fatty acid oxidation and ketogenesis in the brain, while concurrent ketolysis probably occurs in neurons. The increased plasma levels of FFAs during sleep probably support the metabolic shift to lipid metabolism compared with normal wakefulness.
Conclusions
What is the functional significance of fatty acid oxidation in brain astrocytes during the sleeping state? One of the main advantages of fat oxidation is the larger energy yield compared with carbohydrates. For example, complete oxidation of palmitic acid has a 2.4-fold higher yield of ATP per gram than glucose, although requiring correspondingly more oxygen [143] . This stoichiometry would comply with the relatively high oxygen consumption of the sleeping brain, possibly reflecting fundamental differences in synaptic transactions during sleep [5] . Furthermore, fatty acid oxidation produces twice as much metabolic water as glucose [144] , which could be important to avoid excessive water loss from brain tissue and electrolyte imbalances. At the whole-body level, sleep is characterized by absence of muscle tonus, net heat loss and decreased body temperature, and absence of food and water intake. However, oxygen availability remains high, which may favor oxidation of fats over carbohydrates.
Increased long-chain acylcarnitine levels in the brain, as observed during sleep deprivation, can be toxic for cells. For example, the prolonged coma occuring in patients with fatty acid oxidation deficiency caused by mutation in the CPT1A gene may be caused by the accumulation of fatty acids primarily in thalamus and cortex, the more vascularized gray matter brain regions [145] . Likewise, fatty acid oxidation deficiency in Drosophila caused by knock-down of the Cpt2 gene was accompanied by a low survival rate and accumulation of triacylglycerol-rich lipid droplets in the brain and muscle. Conversely, the fly survival rate increased and triacylglycerol accumulation was reversed after rescue of the gene specifically in glial cells [146•] . Thus, we contend that increased fatty acid oxidation acitivity in the sleeping brain will remove and/or recycle unwanted lipid species [147] , and provide energy substrates for glial cells presumably exploiting FFA taken up from the circulation [145] .
One argument against fatty acid oxidation in the brain is that it is ostensibly too slow to meet the increased ATP requirement during rapid neuronal firing [118] . However, this does not apply during slow wave sleep, when high-frequency neuronal oscillations are reduced [148] . The finding that lipids accumulate in the thalamus and cortex of patients with fatty acid oxidation deficiency [145] , and the observation of fast uptake of radioactive labeled palmitate primarily in the thalamus, basal ganglia, and cortex in normal subject [99•] , imply an important function for fatty acid oxidation in these brain regions. The thalamo-cortical circuit receives NE and other monoaminergic innervations that regulate sleep/wake transitions, and the interaction between cortex and thalamus controls the down-states and spindles during non-REM sleep [149] . Thus, local fatty acid oxidation may actively support the sleeping state.
There are currently two notable examples of a direct connection between fatty acid oxidation and sleep. First, very low serum acylcarnitine levels have been reported in 20% of investigated narcolepsy patients carrying a SNP located next to the CPT1B gene, which encodes the muscle-specific isoform of CPT [150] . Administration of L-carnitine to favor fatty acid oxidation activity in such patients restored the levels of acylcarnitines, reduced serum triacylglycerol levels, and shortened the periods of dozing off during day-time [151] . In light of the increased long-chain acylcarnitine levels during sleep deprivation [52••] and the known effect of acylcarnitines in blocking the Na + /K + -ATPase, one might speculate that build-up of acylcarnitines during wakefulness is important for the brain to sustain wakefulness. A second line of evidence linking β-oxidation and sleep is provided by mice with deficiency in the Acads gene, which encodes the shortchain acyl-coenzyme A dehydrogenase involved in oxidation of short-chain fatty acids. This metabolic defect caused a marked slowing in theta frequency during REM sleep, which could be significantly rectified upon treatment with acetyl-L-carnitine to facilitate fatty acid oxidation [152] . Theta oscillations occur in the rodent hippocampus during REM sleep and in the awake state and have been suggested to be important for memory consolidation [153] . Recent findings show that CPT1a-dependent fatty acid oxidation in hippocampal neural progenitor cells is required for stem cell maintenance and neurogenesis, and that switching fatty acid oxidation ON or OFF controls whether the progenitor cells remain quiescent or start to proliferate, respectively [154••] . It is intriguing to speculate about a deep connection between memory consolidation during hippocampal theta wave activity and hippocampal CPT1a-dependent neurogenesis that could manifest in reduced neurogenesis and consequently lower theta-wave activity during REM sleep when fatty acid oxidation is deficient.
The increased levels of brain acylcarnitines during sleep deprivation, which is indicative of incomplete fatty acid oxidation, suggests an important role for this pathway during sleep. At excessive concentrations, acylcarnitines and fatty acids act as detergents on membranes, affecting signaling pathways and inhibiting the Na , potentially leading to induced ROS generation and apoptosis [155, 156] . The process of fatty acid oxidation is inherently an ROS-generating process if not uncoupled [157] , and therefore needs to be accompanied by antioxidant cellular systems [158] . Interestingly, glutathione peroxidase activity measured in rat cerebral cortex homogenates show diurnal cycling, with higher activity and efficiency during the sleep period, while declining during the active period when lipid peroxidation is high due to increased ROS [159••] (Fig. 1a) . Astrocytes are known to synthesize glutathione and can even release it to neurons in cell culture [160] , making astrocytes good candidates for conducting fatty acid oxidation without causing oxidative damage during the sleep state. Notably, sleep up-regulates cerebral expression of genes involved in antioxidant systems [91] .
In conclusion, we have briefly described the current knowledge about specific cerebral metabolic changes occurring during sleep. The literature that we reviewed here indicates that brain activity during sleep, which is fundamentally different from wakefulness, might be supported energetically by fatty acid oxidation.
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